Posted by SLS on May 1, 2016, at 16:23:52
In reply to Re: Does Rexulti affect less receptors then Abilify? » revv33, posted by J Kelly on May 1, 2016, at 12:44:54
Rexulti (brexpiprazole) is less of a D3 dopamine partial receptor agonist than is Abilify. If I understand correctly, there should be less akathisia associated with its use. Rexulti is more active at serotonin 5-HT1a receptors than is Abilify. In addition, Rexulti blocks certain norepinephrine alpha-2 receptors. I don't know what the end result would be of these actions. I guess Rexulti acts as a sort of dopamine-serotonin system modulator.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1088590
URL: http://www.dr-bob.org/babble/20160501/msgs/1088600.html